The Impaired Mechanism and Facilitated Therapies of Efferocytosis in Atherosclerosis

• Published in: Journal of cardiovascular pharmacology Vol. 80; no. 3; pp. 407 - 416
• Main Authors: Wang, Zibin, Su, Jin, Gong, Fanglin, Xue, Lingjing, Su, Zhigui
• Format: Journal Article
• Language: English
• Published: United States Journal of Cardiovascular Pharmacology 01-09-2022
• Subjects: Apoptosis - physiology; Atherosclerosis - drug therapy; Atherosclerosis - metabolism; Humans; Macrophages - metabolism; Phagocytosis - physiology; Plaque, Atherosclerotic - metabolism
• ISSN: 0160-2446; 1533-4023
• DOI: 10.1097/FJC.0000000000001311

Cardiovascular disease is responsible for the largest number of deaths worldwide, and atherosclerosis is the primary cause. Apoptotic cell accumulation in atherosclerotic plaques leads to necrotic core formation and plaque rupture. Emerging findings show that the progression of atherosclerosis appears to suppress the elimination of apoptotic cells. Mechanistically, the reduced edibility of apoptotic cells, insufficient phagocytic capacity of phagocytes, downregulation of bridging molecules, and dysfunction in the polarization of macrophages lead to impaired efferocytosis in atherosclerotic plaques. This review focuses on the characteristics of efferocytosis in plaques and the therapeutic strategies aimed at promoting efferocytosis in atherosclerosis, which would provide novel insights for the development of antiatherosclerotic drugs based on efferocytosis.